SLC38A9

Across TCGA pan-cancer cohorts, SLC38A9 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SLC38A9 data layer compared with 22 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SLC38A9 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC38A9 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, UCEC, and LIHC are the cancer types where SLC38A9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	II,III,IV	0.147	0.612	.016	36	view →
UCEC	DFS	Median	II,III,IV	1.000	0.442	.028	14	view →
LIHC	OS	Median	II,III,IV	0.010	0.716	<.001	12	view →
COAD	DFS	Median	All	0.229	0.696	.017	9	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SLC38A9–HNSC (DFS)

Open the HNSC breakdown →